Phase I-IIa, national, multicenter, clinical trial to evaluate the safety and preliminary efficacy of CAR-T CD19 therapy in patients with refractory lupus nephritis.

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522449-23-00

Enrollment

Registered

2026-06-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Lupus Nephritis

Brief summary

To evaluate the safety and tolerability of CD19 CAR‑T cell therapy (TranspoCART19) in patients with refractory lupus nephritis during the early post‑infusion period (Day 0–28; extended to Day +42 in cases of prolonged cytopenias)

Interventions

DRUGTranspoCART19

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
To evaluate the safety and tolerability of CD19 CAR‑T cell therapy (TranspoCART19) in patients with refractory lupus nephritis during the early post‑infusion period (Day 0–28; extended to Day +42 in cases of prolonged cytopenias)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 12, 2026